EDMONTON, Alberta, May 15, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that both of its two Alberta-based bioprocessing plants, located in Leduc and Edmonton, have received a Site License from the Health Canada Natural and Non-Prescription Health Products Directorate. This license enables the Company to fabricate, package, label, release and distribute final products.
“We are very pleased with the issuance of this license recognizing that our state-of-the-art bioprocessing sites are in compliance with GMP requirements of the Natural Health Products Regulations. Receiving this is a further testament of the Quality Management System being implemented at Ceapro, which has also been recognized by major customers during their audits conducted at the end of 2018. Importantly, the issuance of this license is another important milestone in the transition of Ceapro’s business model from a contract manufacturer to a biopharmaceutical company. This license will enable us to not only produce and sell active ingredients as raw material, but will also allow Ceapro to manufacture and release its own finished products, such as beta glucan tablets and other PGX-processed new chemical entities,” commented Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro.
About Ceapro Inc.
Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions.
For more information on Ceapro, please visit the Company’s website at www.ceapro.com.
For more information contact:
Jenene Thomas
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T (US): +1 (833) 475-8247
E: czo@jtcir.com
Issuer:
Gilles R. Gagnon, M.Sc., MBA
President & CEO
T: 780-421-4555
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release
